# A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

> **NCT06905197** · PHASE1 · RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 140 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** DZD6008
- **DRUG:** Sunvozertinib

## Key facts

- **NCT ID:** NCT06905197
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2027-09
- **Final completion:** 2028-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905197, "A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06905197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*